title: [Phezam efficacy in patients with chronic cerebral ischemic disease].
abstract: The efficacy of combined medication which comprised compounds with nootropic (piracetam) and vasoactive (cinnarisin) effects, was studied in patients with cerebral blood flow insufficiency. The main inclusion criterion was a diagnosis of chronic brain ischemia (CI). The study consisted of two stages: (1) a randomized comparative trial in neurological clinic (60 patients) and (2) estimation of the drug efficacy in routine practice (60 patients). The clinical examination was accompanied by neuropsychological tasks, kinetic tests and ultrasound investigation of brain vessels. At the first stage, a positive neurological and neuropsychological dynamics was found after 8 weeks of phezam treatment. Also a statistically significant positive dynamics was observed for a number of blood flow velocity parameters in the middle brain artery. In routine medical practice, a positive effect of phezam was seen after 2 months of the treatment for all but CI main symptoms and confirmed by the data of kinetic investigation. The patients reported good tolerability and convenience of the drug intake (one capsule instead of two tablets of nootropic and vasoactive drugs).
authors.forename: A N
authors.initials: AN
authors.lastname: Boĭko
authors.forename: A A
authors.initials: AA
authors.lastname: Kabanov
authors.forename: T A
authors.initials: TA
authors.lastname: Es'kina
authors.forename: L A
authors.initials: LA
authors.lastname: Sheliakina
authors.forename: A I
authors.initials: AI
authors.lastname: Shchukin
authors.forename: T T
authors.initials: TT
authors.lastname: Batysheva
authors.forename: I Iu
authors.initials: IIu
authors.lastname: Artemova
authors.forename: T V
authors.initials: TV
authors.lastname: Vdovichenko
authors.forename: S A
authors.initials: SA
authors.lastname: Volovets
authors.forename: P A
authors.initials: PA
authors.lastname: Ganzhula
mesh_terms: D000368:Aged; D001921:Brain / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology; D002545:Brain Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002908:Chronic Disease; D002936:Cinnarizine / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018697:Nootropic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010889:Piracetam / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D002121:Calcium Channel Blockers; D004338:Drug Combinations; D018697:Nootropic Agents; C500648:phezam; D002936:Cinnarizine; D010889:Piracetam